Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · IEX Real-Time Price · USD
28.30
+0.66 (2.39%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Arrowhead Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for ARWR stock have an average target of 44.25, with a low estimate of 27 and a high estimate of 60. The average target predicts an increase of 56.36% from the current stock price of 28.30.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ARWR stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 4 | 4 |
| Buy | 5 | 5 | 5 | 4 | 3 | 3 |
| Hold | 4 | 4 | 4 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $60 | Strong Buy | Maintains | $60 | +112.01% | Jul 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $90 → $60 | Strong Buy | Maintains | $90 → $60 | +112.01% | Jul 5, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $60 | Strong Buy | Maintains | $60 | +112.01% | Jun 26, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +218.02% | Jun 11, 2024 |
Financial Forecast
Revenue This Year
100.61M
from 240.74M
Decreased by -58.21%
Revenue Next Year
138.05M
from 100.61M
Increased by 37.21%
EPS This Year
-3.43
from -1.92
EPS Next Year
-3.11
from -3.43
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 266.3M | 300.4M | 423.2M | 746.8M | 1.3B |
| Avg | 100.6M | 138.1M | 237.5M | 471.8M | 830.6M |
| Low | 52.5M | n/a | 116.4M | 213.9M | 288.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 10.6% | 198.6% | 206.5% | 214.4% | 174.7% |
| Avg | -58.2% | 37.2% | 72.0% | 98.7% | 76.0% |
| Low | -78.2% | - | -15.7% | -9.9% | -38.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.04 | -1.53 | -0.16 | 1.50 | 3.58 |
| Avg | -3.43 | -3.11 | -2.57 | -0.36 | 1.72 |
| Low | -4.48 | -5.03 | -4.05 | -2.60 | 0.42 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.